GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Cyclically Adjusted PB Ratio

Viatris (Viatris) Cyclically Adjusted PB Ratio : 0.50 (As of Apr. 27, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Viatris Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Viatris's current share price is $11.57. Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $23.02. Viatris's Cyclically Adjusted PB Ratio for today is 0.50.

The historical rank and industry rank for Viatris's Cyclically Adjusted PB Ratio or its related term are showing as below:

VTRS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.38   Med: 2.28   Max: 8.54
Current: 0.5

During the past years, Viatris's highest Cyclically Adjusted PB Ratio was 8.54. The lowest was 0.38. And the median was 2.28.

VTRS's Cyclically Adjusted PB Ratio is ranked better than
85.78% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs VTRS: 0.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viatris's adjusted book value per share data for the three months ended in Dec. 2023 was $17.045. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $23.02 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Viatris Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Viatris's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Cyclically Adjusted PB Ratio Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.22 1.05 0.69 0.52 0.47

Viatris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.43 0.44 0.43 0.47

Competitive Comparison of Viatris's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Cyclically Adjusted PB Ratio falls into.



Viatris Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Viatris's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.57/23.02
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Viatris's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=17.045/129.4194*129.4194
=17.045

Current CPI (Dec. 2023) = 129.4194.

Viatris Quarterly Data

Book Value per Share CPI Adj_Book
201403 8.500 99.695 11.034
201406 8.915 100.560 11.474
201409 9.054 100.428 11.668
201412 8.677 99.070 11.335
201503 18.536 99.621 24.080
201506 19.465 100.684 25.020
201509 19.957 100.392 25.728
201512 19.902 99.792 25.811
201603 20.908 100.470 26.932
201606 20.318 101.688 25.859
201609 22.104 101.861 28.084
201612 20.765 101.863 26.383
201703 21.749 102.862 27.364
201706 23.937 103.349 29.975
201709 24.782 104.136 30.799
201712 25.386 104.011 31.587
201803 25.567 105.290 31.426
201806 23.682 106.317 28.828
201809 23.402 106.507 28.436
201812 23.589 105.998 28.801
201903 23.026 107.251 27.786
201906 23.074 108.070 27.632
201909 22.210 108.329 26.534
201912 23.024 108.420 27.483
202003 21.787 108.902 25.892
202006 22.722 108.767 27.036
202009 24.273 109.815 28.606
202012 19.019 109.897 22.398
202103 17.720 111.754 20.521
202106 17.538 114.631 19.800
202109 17.481 115.734 19.548
202112 16.943 117.630 18.641
202203 16.867 121.301 17.996
202206 16.335 125.017 16.910
202209 15.818 125.227 16.348
202212 17.361 125.222 17.943
202303 17.151 127.348 17.430
202306 17.382 128.729 17.475
202309 17.393 129.860 17.334
202312 17.045 129.419 17.045

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Viatris  (NAS:VTRS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Viatris Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris (Viatris) Business Description

Industry
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
Andrew Cuneo officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni officer: President, Greater China 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury director, officer: Executive Chairman BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell director
Brian Roman officer: Global General Counsel 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts director 120 PARK AVE, NEW YORK NY 10017
Melina E Higgins director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL